ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,438.00
      0.20%
      US Tech 100
      18,555.00
      0.11%
      Dow Jones
      40,138.60
      0.71%
      Brent Oil
      81.455
      0.89%
      Bitcoin
      64,669.14
      -1.08%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Kyverna Therapeutics Inc (KYTX) Quote

      Kyverna Therapeutics Inc

      Kyverna Therapeutics Inc (KYTX)

      NASDAQ
      8.92
      0.00
      ( 0.00% )
      Updated: 14:30:13
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      8.92
      Bid
      8.91
      Ask
      8.98
      Volume
      156,463
      8.91 Day's Range 9.28
      6.75 52 Week Range 35.01
      Market Cap
      384.588M
      Previous Close
      8.92
      Open
      9.00
      Last Trade
      1
      @
      8.9386
      Last Trade Time
      14:30:15
      Financial Volume
      $ 1,418,579
      VWAP
      9.0665
      Average Volume (3m)
      630,509
      Shares Outstanding
      43,115,244
      Dividend Yield
      -
      PE Ratio
      -6.36
      Earnings Per Share (EPS)
      -1.4
      Revenue
      -
      Net Profit
      -60.37M

      About Kyverna Therapeutics Inc

      Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin... Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      kyvernatx.com
      Headquarters
      Dover, Delaware, USA
      Founded
      1970
      Kyverna Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KYTX. The last closing price for Kyverna Therapeutics was $8.92. Over the last year, Kyverna Therapeutics shares have traded in a share price range of $ 6.75 to $ 35.01.

      Kyverna Therapeutics currently has 43,115,244 shares outstanding. The market capitalization of Kyverna Therapeutics is $384.59 million. Kyverna Therapeutics has a price to earnings ratio (PE ratio) of -6.36.

      KYTX Latest News

      More News

      FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

      7 hours ago

      Form 8-K - Current report

      July 15 2024
      Edgar (US Regulatory)

      Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

      Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome PR Newswire EMERYVILLE, Calif., July 15, 2024 The application...

      July 15 2024
      PR Newswire (US)

      Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

      Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial PR Newswire EMERYVILLE, Calif., June 20...

      June 20 2024
      PR Newswire (US)

      First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

      First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) PR Newswire EMERYVILLE...

      June 17 2024
      PR Newswire (US)

      Form 8-K - Current report

      June 14 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 10 2024
      Edgar (US Regulatory)

      Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

      Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology PR Newswire EMERYVILLE, Calif., June 10, 2024...

      June 10 2024
      PR Newswire (US)

      Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

      Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 PR Newswire EMERYVILLE, Calif., June 7, 2024 Data to include insights from 12 indications from more than...

      June 07 2024
      PR Newswire (US)

      Form 4 - Statement of changes in beneficial ownership of securities

      May 29 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.88-17.407407407410.811.248.813681519.81216007CS
      41.8425.9887005657.0811.46.8956010958.68084624CS
      12-7.64-46.135265700516.5617.556.7563050910.46365962CS
      26-25.33-73.956204379634.2535.016.7553629116.37842885CS
      52-25.33-73.956204379634.2535.016.7553629116.37842885CS
      156-25.33-73.956204379634.2535.016.7553629116.37842885CS
      260-25.33-73.956204379634.2535.016.7553629116.37842885CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      NVNINVNI Group Ltd
      $ 2.34
      (93.39%)
      		976.01k
      POAIPredictive Oncology Inc
      $ 1.88
      (75.70%)
      		153.76M
      PBMPsyence Biomedical Ltd
      $ 0.6389
      (63.23%)
      		78.8M
      SLRXSalarius Pharmaceuticals Inc
      $ 3.1501
      (47.20%)
      		29.32M
      CMAXCareMax Inc
      $ 5.625
      (44.97%)
      		20.71M
      TWOU2U Inc
      $ 1.5323
      (-62.81%)
      		4.63M
      EZFLEzFill Holdings Inc
      $ 3.75
      (-39.76%)
      		167.39k
      KDLYKindly MD Inc
      $ 2.11
      (-34.47%)
      		734.08k
      CTNTCheetah Net Supply Chain Service Inc
      $ 0.3235
      (-32.88%)
      		10.94M
      SLGLSol Gel Technologies Ltd
      $ 0.4554
      (-32.03%)
      		14.15M
      NVDANVIDIA Corporation
      $ 114.25
      (0.00%)
      		362.64M
      SQQQProShares UltraPro Short QQQ
      $ 9.0763
      (0.18%)
      		207.86M
      SLNASelina Hospitality PLC
      $ 0.03985
      (-12.80%)
      		168.47M
      POAIPredictive Oncology Inc
      $ 1.89
      (76.64%)
      		153.76M
      TSLATesla Inc
      $ 224.46
      (3.92%)
      		79.48M

      Discussion

      View Full Feed
      everton44 everton44 21 seconds ago
      Can you ever stop pump and dumping?
      HIRU
      hweb2 hweb2 27 seconds ago
      Good luck with PSIX. Sounds like you'll be getting back in soon. Buying a stock up 500% since May...into what is likely to be a flattish comp next month...sounds incredibly dangerous to me, but to each their own.

      Not sure if mentioned here before, but it appears PSIX may exhaust the
      Gold prospector Gold prospector 31 seconds ago
      Someone just picked up a bunch of shares!
      LGIQ
      DUBBALRNVS DUBBALRNVS 35 seconds ago
      my guess he wants it at .0026 to cover lol
      HIRU
      HigherStandard HigherStandard 51 seconds ago
      Now 14 x 15. I'm thinking an update or PR anytime;
      As been saying all along....book value apx. .005, without any merger or acquisition;
      Gem em while you can IMO
      GGSM
      nelson1234 nelson1234 1 minute ago
      BT I was thinking of doing the long B short A arb before earnings, but I guess I'm just not a big arb guy.
      BearRickPunch BearRickPunch 1 minute ago
      Is that more than the $8 from a year ago?
      ERHE
      NASDAQ2020 NASDAQ2020 1 minute ago
      It was after you sold all your shares at 15
      ELTP
      georgejjl georgejjl 1 minute ago
      Coming presentations by Anavex

      26 July 2024 three presentations concerning Anavex at the Fragile X conference

      27 July 2024 one presentation regarding Anavex at the Fragile X conference

      28 July 2024 one presentation concerning Anavex at the Alzheimer’s dis
      AVXL
      QuantumTravesty QuantumTravesty 1 minute ago
      Honestly I tried but I have to put you on iggy. There is no “market sell” in the otc and I’m a stickler for details. Especially from known liars.
      HIRU
      jobynimble jobynimble 1 minute ago
      SPARC AI COMPLETES A SUCCESSFUL DRONE FLIGHT

      July 24, 2024 – Toronto, Canada – SPARC AI INC. (CSE: SPAI) (OTC: SPAIF) (“SPAI” or the “Company”), is pleased to announce that the Company has successfully completed a first flight with a SPARC AI enabled ANAFI USA drone. SPARC AI recorde
      GPS SPAI
      johny1 johny1 1 minute ago
      BTO SPY 541 P@.52
      CatfishHunter CatfishHunter 1 minute ago
      Dude. You’re grasping at thin air. MMs are closing out their short positions. They know good news is high probability. Also a few retail are closing out not wanting to risk small profits waiting for news. The CEO korenko doesn’t leak news. And if FDA was going to deny, they would have done that al
      RDGL
      Milesblue42 Milesblue42 1 minute ago
      I'm seeing .0015. News Pending? Trading Halt..or Nothing?

      Interesting market maker CSTI at 25 cents

      Are these questions....okay? 🙂
      GGSM
      Doc logic Doc logic 2 minutes ago
      FeMike,

      Everything hinges on Flaskworks. Partnership trials, planned combo trials at UCLA, franchise deals. Even L reimbursement depends very likely on Flaskworks. Once Flaskworks hits everything else falls into place. This being said, approval makes anticipation of Flaskworks com
      NWBO
      Itchy palm Itchy palm 2 minutes ago
      Just read US economy grew 2.8 % in second quarter this year 😁
      benz280e benz280e 2 minutes ago
      Bleak…
      GDVM
      Nebuchadnezzar Nebuchadnezzar 2 minutes ago
      remember the bear market rallies of 2022? that's what today is, nothing more, the sheep will be slaughtered

      massive funds have to sell stocks before year end bc they didnt sell in 2023

      rate cut cycle will also be finite or short lived

      inflation will neve
      NVDA
      janetcanada janetcanada 2 minutes ago
      HIRU - You are trying so hard!.... You mean you cannot take down???...

      👀***HIRU -***Insider Trading Screener- Enter Symbol....
      🔥***165 MIllion***.....🔥

      👀*&#
      HIRU
      biotechinvestor1 biotechinvestor1 2 minutes ago
      Those are pre-programmed sales. They have been selling every year since the stock was in single digits and teens. They did not forecast a decline in share price back then and they do not now.

      These pre-programmed sales are part of personal portfolio diversification and routine.
      HALO
      leverage102 leverage102 2 minutes ago
      IMO, NSAV IS BOSS WITHIN THE CEX SPACE. Don't Crown another established CEX.. Give NSAV ONE YEAr AND YOU CAN Be rICH $$$$. * Opportunities in the middle; just be ready for the STAMPED $$$$$$
      NSAV
      chilar4567 chilar4567 2 minutes ago
      If pps breaks $7.50 by DECEMBER, I'll be out. With an extremely healthy boat load of cash
      PAYS
      JakBqk JakBqk 3 minutes ago
      Yep,Every sub penny is Waiting on funds, ,,,soon,
      😆
      Until then we get everything you described when trying to sort through the bs..
      PHIL
      Carjockey2 Carjockey2 3 minutes ago
      Can somebody remove this spam thank you moderators
      HIRU
      dstock07734 dstock07734 3 minutes ago
      IC,

      Just let you know. I have a boma free of charge you are broke.

      https://investorshub.advfn.com/uimage/uploads/2024/6/28/lpslcFifteen_different_drugs.jpg

      https://investorshub.advfn.com/uimage/uploads/2024/5/1/tmbqmLesGoldMan_800.png
      NWBO

      Your Recent History

      NASDAQ
      KYTX
      Kyverna Therapeutics
      Delayed Upgrade Clock